# GSK’s Arexvy RSV vaccine approved for adults 50-59 at risk of LRTD

- Link: https://www.directorstalkinterviews.com/gsks-arexvy-rsv-vaccine-approved-for-adults-50-59-at-risk-of-lrtd/4121159618
- Published: 2024-06-10T07:17:51+01:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**(
LON/NYSE:) has announced that the US Food and Drug Administration (FDA) has approved
_Arexvy_ (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention
of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years of age
who are at increased risk. In the US, the vaccine is currently approved for use 
in adults aged 60 and older and recommended by CDC/ACIP using shared clinical decision-
making.

·   Over 13 million US adults aged 50-59 years have a medical condition that increases
their risk of severe RSV outcomes^([1])

·   Clinical development programme continues to evaluate safety and immunogenicity
in adults 18+ with data read-outs expected H2 2024

A systematic review of studies in the US showed that RSV is estimated to cause 42,000
hospitalisations^(*) each year in adults aged 50-64 years old.^([2]) Adults with
underlying medical conditions, such as chronic obstructive pulmonary disease (COPD),
asthma, heart failure and diabetes^([3]) are at increased risk for severe consequences
from an RSV infection compared to those without these conditions. RSV can exacerbate
these conditions and lead to pneumonia, hospitalisation or death.^([4])

^(*)adjusted for under-detection

**Tony Wood, Chief Scientific Officer, GSK, said**: “Today’s approval reflects the
importance of broadening the benefits of RSV immunisation to adults aged 50-59 who
are at increased risk. For those with underlying medical conditions, RSV can have
serious consequences, so we are proud to be the first to help protect them from 
RSV-LRTD.”

The regulatory application was supported by positive results from a phase III trial[
NCT05590403]^([5]) evaluating the immune response and safety of GSK’s RSV vaccine
in adults aged 50-59, including those at increased risk for RSV-LRTD due to certain
underlying medical conditions.

> **Professor Ann R. Falsey, University of Rochester School of Medicine, said**:“
> I am thrilled that GSK’s RSV vaccine is now approved for adults aged 50-59 at 
> increased risk of RSV-LRTD. When it comes to the risks associated with RSV, age
> is just a number, an important number, but not the only factor to consider. Many
> adults in this age group have underlying health conditions that place them at 
> increased risk for serious illness with RSV infection compared with those without
> these conditions. Now there is a vaccine approved that can help protect them.”

GSK has also filed regulatory submissions to extend the use of its RSV vaccine to
adults aged 50-59 at increased risk in Europe, Japan and other geographies with 
regulatory decisions undergoing review. Trials evaluating the immunogenicity and
safety of the vaccine in adults aged 18-49 at increased risk and immunocompromised
adults aged 18 and over are expected to read out in H2 2024.

Share on:
